DFPH SEC filings, in plain English
Everything DFP HEALTHCARE ACQUISITIONS CORP. has filed with the SEC that we hold — 40 filings, newest first, 6 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Starling Oncology, Inc. filed an 8-K on August 21, 2026, reporting the entry into a $25 million revolving credit agreement with Gemino Healthcare Finance, LLC dated August 20, 2026, with $4,750,000 outstanding as of the closing date and maturity on August 20, 2029. Why it matters: This filing does not contain information regarding DFP HEALTHCARE ACQUISITIONS CORP.'s redemption deadlines, trust value, or extension status as the SPAC is closed; it solely reports new debt obligations for the acquired entity Starling Oncology.
What changed: Starling Oncology, Inc. (Nasdaq: STLN), formerly The Oncology Institute, furnished a press release reporting second quarter 2026 results. Consolidated revenue was $161.3 million, up 34.6% from $119.8 million, gross profit $27.2 million, up 55.2%, and the net loss narrowed to $9.8 million from $17.0 million, or $(0.08) per share against $(0.15); adjusted EBITDA turned positive at $229 thousand against a $4.1 million loss, and cash was $41.1 million. Specialty Pharmacy revenue rose 58% on record Part D fills. Why it matters: Revenue and gross profit guidance both went up while the top of the adjusted EBITDA range came down from $9 million to $7 million — the growth is arriving at lower incremental profitability, which is consistent with Specialty Pharmacy leading it. The 230,000 additional capitated lives are added at a stated 80% to 90% medical loss ratio, so most of that revenue is spoken for by claims.
What changed: The 10-Q filed under Commission file number 001-39248 is that of Starling Oncology, Inc. (Nasdaq: STLN), formerly The Oncology Institute, for the quarter ended June 30, 2026, with 101,916,115 shares outstanding as of July 30, 2026 and warrants at $11.50 still trading under the legacy symbol TOIIW. Total operating revenue was $161,282 thousand against $119,802 thousand, of which Specialty Pharmacy was $98,608 thousand against $62,573 thousand and patient services $58,827 thousand against $55,891 thousand; direct costs of specialty pharmacy were $77,346 thousand. Why it matters: Specialty Pharmacy is now 61% of revenue at a direct margin of about 22%, so the revenue growth is coming from the lower-margin half of the business — which is why operating losses narrow more slowly than revenue grows. Accounts payable rose $17.1 million while cash rose $7.5 million, so part of the cash improvement is slower payment rather than earnings.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements. The Company”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: 8-K of The Oncology Institute, Inc. Item 5.03 (amendments to articles of incorporation): on July 28, 2026 the Company filed a Certificate of Amendment in Delaware changing its name to Starling Oncology, Inc., effective immediately; no stockholder approval was required under DGCL Section 242 because the amendment related only to the name. The common stock begins trading on Nasdaq as STLN on August 3, 2026. The report states neither the name nor the symbol change affects stockholder rights and the CUSIP remains 68236X100. Item 7.01 furnishes an August 3, 2026 press release. Why it matters: An identity change with no economic effect stated: same CUSIP, same rights, new ticker. It matters mainly to anything keyed on the old name or the TOI symbol. The signature block still executes the report as THE ONCOLOGY INSTITUTE, INC. on August 3, after the new name took effect.
What changed: The Oncology Institute, Inc., the DFP Healthcare Acquisitions Corp. successor, filed as Exhibit 10.1 a Credit Agreement dated July 1, 2026 with OrbiMed Opportunities (CA) V LLC as initial lender and administrative agent. It sets out borrowing procedures, amortisation, repayment and prepayment terms, SOFR-based interest with a default rate, and conditions including payment of outstanding indebtedness, guarantees, security agreements, intellectual property security agreements, solvency certificates and no material adverse effect. Why it matters: A credit facility from a healthcare-focused lender secured on assets and intellectual property, with guarantees and solvency certification as closing conditions, is the profile of financing extended to a company that cannot access unsecured bank debt. The intellectual property security agreements matter most for former DFPH holders: pledging IP means the lender can take the company's core assets on default, and conditions such as payment of outstanding indebtedness indicate this facility refinances existing borrowings rather than adding new capacity.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements. The Company”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: The Oncology Institute, Inc., the successor to DFP Healthcare Acquisitions Corp., noticed its annual meeting for Wednesday, June 17, 2026 at 11:00 a.m. Pacific Time as a fully virtual meeting at proxydocs.com/TOI, record date April 24, 2026, with each share of common stock carrying one vote. The proxy recaps that the business combination with TOI Parent, Inc. closed November 12, 2021 under a merger agreement dated June 28, 2021 among DFP Healthcare Acquisitions Corp., Orion Merger Sub I, Orion Merger Sub II and TOI Parent. Why it matters: Routine annual governance almost five years after the DFP trust was released - no redemption right, deadline or floor remains for former SPAC holders. The single number worth carrying forward is the $174.51 TSR value for 2025 against a much weaker 2024 comparison, which shows the equity re-rating well after the de-SPAC even as the company continued to report a net loss.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.